IL5 and asthma: In line with the promising results of IL-5–targeted therapy for bronchiectasis without asthma reported by Rademacher et al,26 we found patients with bronchiectasis to have significantly elevated levels of sputum eosinophils, which have been linked with a predominantly IL-5–driven disease.